Bolt Biotherapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $26.0K | $2.5M | $2.2M | $1.8M | $1.2M | $0 | $1.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.1M | $4.8M | $5.0M | $6.5M | $7.5M | $9.5M | $11.7M | $13.8M |
| SG&A Expense | $2.4M | $2.8M | $3.1M | $3.3M | $3.5M | $3.8M | $3.9M | $3.8M |
| Operating Income | $-8.4M | $-7.6M | $-7.1M | $-7.7M | $-9.2M | $-12.1M | $-16.9M | $-16.4M |
| Operating Margin | -167,480.0% | -29,234.6% | -283.4% | -355.1% | -510.5% | -991.4% | — | -1,441.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-7.7M | $-7.2M | $-6.6M | $-7.1M | $-8.6M | $-11.0M | $-15.9M | $-15.2M |
| Net Margin | -154,400.0% | -27,861.5% | -265.2% | -329.4% | -474.6% | -903.4% | — | -1,330.1% |
| EPS (Basic) | $-4.57 | $-4.31 | $-3.91 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 |
| EPS (Diluted) | $-4.57 | $-4.31 | $-3.91 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 |
| Shares Outstanding (Basic) | 1.7M | 1.7M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M |
| Shares Outstanding (Diluted) | 1.7M | 1.7M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |